- Acumen Pharmaceuticals has extended its collaboration with Lonza to prepare for the potential commercial launch of sabirnetug (ACU193), a novel Alzheimer’s treatment.
- The extended deal includes manufacturing support for ongoing and future clinical trials, as well as for potential commercial production.
Acumen Pharmaceuticals has announced an extension of its partnership with Lonza to prepare for the future commercial launch of sabirnetug (ACU193), a novel therapeutic targeting Alzheimer’s disease (AD). Sabirnetug is the first humanized monoclonal antibody to selectively engage toxic soluble amyloid beta oligomers (AβOs), a key trigger of early neurodegeneration in AD patients.
The extended agreement builds on an existing relationship, where Lonza has provided drug substance (DS) manufacturing for Acumen’s Phase 2 trials. The collaboration now includes cGMP drug product (DP) manufacturing, quality control, and stability testing at Lonza’s state-of-the-art facility in Visp, Switzerland. This will support the ongoing and future clinical phases of sabirnetug and potentially its commercial launch.
James Doherty, President and Chief Development Officer of Acumen, noted, “The extension of our collaboration comes at a time when we’re advancing our clinical programs for sabirnetug with more than 50 Phase 2 sites activated across the U.S., Canada, U.K., and EU.” The company is currently enrolling patients in its ALTITUDE study, evaluating the safety and efficacy of sabirnetug in patients with early AD.
Lonza’s Peter Droc, Head of Drug Product Services, commented, “We are looking forward to collaborating with Acumen to advance its innovative and promising drug candidate in the clinic and beyond.”
Overview of outsourcing trends 
